HealthCare Global Enterprises (HCG) is planning a major expansion by adding over 1,000 beds across India, with a strong focus on Tier-II cities. The move aims to address the rising demand for specialized cancer care and improve accessibility beyond metro regions.
Glimpse:
Announced in April 2026, HCG plans to add at least 1,000 beds over the next five years, increasing its current capacity of around 2,500 beds. The expansion will include both new hospitals and upgrades to existing facilities, supported by investment from KKR. The strategy focuses on Tier-II cities to bridge gaps in oncology care access while scaling advanced treatment capabilities.
HealthCare Global Enterprises (HCG), a leading oncology focused healthcare provider in India, has announced plans to significantly expand its capacity by adding over 1,000 beds in the next five years. This expansion will increase its total bed count from approximately 2,500 to over 3,500, reflecting the growing demand for specialized cancer treatment across the country.
The expansion strategy will be executed through a combination of greenfield projects and brownfield expansions. Around 400 beds are expected to come from new facilities, while an additional 500–600 beds will be added by upgrading existing hospitals.
A key focus of this growth plan is Tier-II cities, where access to advanced oncology care remains limited. By expanding into these regions, HCG aims to decentralize cancer care and reduce the burden on metro hospitals, making high quality treatment more accessible to a wider population.
The expansion is backed by investment from global private equity firm KKR, which is supporting HCG’s growth through both organic expansion and potential mergers and acquisitions. This strategic backing is expected to accelerate the company’s ability to scale operations and strengthen its position in India’s rapidly growing oncology market.
HCG is also focusing on enhancing its clinical capabilities by investing in advanced technologies such as precision oncology, robotic surgery, and AI-driven diagnostics. The company aims to attract complex cancer cases and improve patient outcomes while maintaining operational efficiency.
However, the expansion comes amid increasing competition from major hospital chains like Apollo Hospitals, Max Healthcare, and Fortis Healthcare, all of which are also investing heavily in capacity and specialized services. This makes execution, clinical quality, and scalability critical factors for HCG’s long-term success.
“Clinical excellence and patient outcomes not just scale will drive our growth.”
By
HB Team
Related News
